Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.07.2023 | News item

Pralsetinib-related tuberculosis

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

The Ireland Health Products Regulatory Authority (HPRA) has published a Direct Healthcare Professional Communication from Roche Products (Ireland), in agreement with the European Medicines Agency and the HPRA, advising that tuberculosis (TB; mostly extrapulmonary) has been reported in patients receiving pralsetinib [Gavreto] for the treatment of rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer. …

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Hyaluronic-acid

Case report

Antiretrovirals

Case report

Multiple drugs

Case report

Antineoplastics